Top

BMC Cancer

Published in:

Open Access 01-12-2021 | Gastric Cancer | Research

A novel ferroptosis-related lncRNA signature for prognosis prediction in gastric cancer

Authors: Jianming Wei, Ye Zeng, Xibo Gao, Tong Liu

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

Gastric cancer (GC) is a common malignant cancer with a poor prognosis. Ferroptosis has been shown to play crucial roles in GC development. Long non-coding RNAs (lncRNAs) is also associated with tumor progression in GC. This study aimed to screen the prognostic ferroptosis-related lncRNAs and to construct a prognostic risk model for GC.

Methods

Ferroptosis-related lncRNAs from The Cancer Genome Atlas (TCGA) GC expression data was downloaded. First, single factor Cox proportional hazard regression analysis was used to select seven prognostic ferroptosis-related lncRNAs from TCGA database. And then, the selected lncRNAs were further included in the multivariate Cox proportional hazard regression analysis to establish the prognostic model. A nomogram was constructed to predict individual survival probability. Finally, we performed quantitative reverse transcription polymerase chain reaction (qRT-PCR) to verify the risk model.

Results

We constructed a prognostic ferroptosis-related lncRNA signature in this study. Kaplan-Meier curve analysis revealed a significantly better prognosis for the low-risk group than for the high-risk group (P = 2.036e-05). Multivariate Cox proportional risk regression analysis demonstrated that risk score was an independent prognostic factor [hazard ratio (HR) = 1.798, 95% confidence interval (CI) =1.410–2.291, P < 0.001]. A nomogram, receiver operating characteristic curve, and principal component analysis were used to predict individual prognosis. Finally, the expression levels of AP003392.1, AC245041.2, AP001271.1, and BOLA3-AS1 in GC cell lines and normal cell lines were tested by qRT-PCR.

Conclusions

This risk model was shown to be a novel method for predicting prognosis for GC patients.

Available only for authorised users

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492.CrossRefPubMed

Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32. https://doi.org/10.3322/caac.21338.CrossRefPubMed

Eusebi LH, Telese A, Marasco G, Bazzoli F, Zagari RM. Gastric cancer prevention strategies: a global perspective. J Gastroenterol Hepatol. 2020;35(9):1495–502. https://doi.org/10.1111/jgh.15037.CrossRefPubMed

Mou Y, Wang J, Wu J, He D, Zhang C, Duan C, et al. Ferroptosis, a new form of cell death: opportunities and challenges in cancer. J Hematol Oncol. 2019;12(1):34. https://doi.org/10.1186/s13045-019-0720-y.CrossRefPubMedPubMedCentral

Kang R, Zhu S, Zeh HJ, Klionsky DJ, Tang D. BECN1 is a new driver of ferroptosis. Autophagy. 2018;14(12):2173–5.CrossRefPubMedPubMedCentral

Roh JL, Kim EH, Jang H, Shin D. Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis. Redox Biol. 2017;11:254–62. https://doi.org/10.1016/j.redox.2016.12.010.CrossRefPubMed

Sun X, Niu X, Chen R, He W, Chen D, Kang R, et al. Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis. Hepatology. 2016;64(2):488–500. https://doi.org/10.1002/hep.28574.CrossRefPubMed

Zhang H, Deng T, Liu R, Ning T, Yang H, Liu D, et al. CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer. Mol Cancer. 2020;19(1):43. https://doi.org/10.1186/s12943-020-01168-8.CrossRefPubMedPubMedCentral

Shin D, Kim EH, Lee J, Roh JL. Nrf2 inhibition reverses resistance to GPX4 inhibitor-induced ferroptosis in head and neck cancer. Free Radic Biol Med. 2018;129:454–62. https://doi.org/10.1016/j.freeradbiomed.2018.10.426.CrossRefPubMed

10.

Cao C, Sun G, Liu C. Long non-coding RNA SNHG6 regulates the sensitivity of prostate cancer cells to paclitaxel by sponging miR-186. Cancer Cell Int. 2020;20(1):381. https://doi.org/10.1186/s12935-020-01462-x.CrossRefPubMedPubMedCentral

11.

Schmitz SU, Grote P, Herrmann BG. Mechanisms of long noncoding RNA function in development and disease. Cell Mol Life Sci CMLS. 2016;73(13):2491–509. https://doi.org/10.1007/s00018-016-2174-5.CrossRefPubMed

12.

Bhan A, Soleimani M, Mandal SS. Long noncoding RNA and Cancer: a new paradigm. Cancer Res. 2017;77(15):3965–81. https://doi.org/10.1158/0008-5472.CAN-16-2634.CrossRefPubMedPubMedCentral

13.

Torres-Bayona S, Aldaz P, Auzmendi-Iriarte J, Saenz-Antoñanzas A, Garcia I, Arrazola M, et al. PR-LncRNA signature regulates glioma cell activity through expression of SOX factors. Sci Rep. 2018;8(1):12746. https://doi.org/10.1038/s41598-018-30836-5.CrossRefPubMedPubMedCentral

14.

Huang GW, Xue YJ, Wu ZY, Xu XE, Wu JY, Cao HH, et al. A three-lncRNA signature predicts overall survival and disease-free survival in patients with esophageal squamous cell carcinoma. BMC Cancer. 2018;18(1):147. https://doi.org/10.1186/s12885-018-4058-6.CrossRefPubMedPubMedCentral

15.

Chen SH, Lin F, Zhu JM, Ke ZB, Lin TT, Lin YZ, et al. An immune-related lncRNA prognostic model in papillary renal cell carcinoma: A lncRNA expression analysis. Genomics. 2020;113(1):531–40. https://doi.org/10.1016/j.ygeno.2020.09.046.CrossRefPubMed

16.

Mi JX, Zhang YN, Lai Z, Li W, Zhou L, Zhong F. Principal component analysis based on nuclear norm minimization. Neural Netw. 2019;118:1–16. https://doi.org/10.1016/j.neunet.2019.05.020.CrossRefPubMed

17.

Wei J, Wang J, Gao X, Qi F. Identification of differentially expressed circRNAs and a novel hsa_circ_0000144 that promote tumor growth in gastric cancer. Cancer Cell Int. 2019;19(1):268. https://doi.org/10.1186/s12935-019-0975-y.CrossRefPubMedPubMedCentral

18.

Qiu J, Sun M, Wang Y, Chen B. Identification and validation of an individualized autophagy-clinical prognostic index in gastric cancer patients. Cancer Cell Int. 2020;20(1):178. https://doi.org/10.1186/s12935-020-01267-y.CrossRefPubMedPubMedCentral

19.

Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060–72. https://doi.org/10.1016/j.cell.2012.03.042.CrossRefPubMedPubMedCentral

20.

Hao S, Yu J, He W, Huang Q, Zhao Y, Liang B, et al. Cysteine dioxygenase 1 mediates Erastin-induced Ferroptosis in human gastric Cancer cells. Neoplasia. 2017;19(12):1022–32. https://doi.org/10.1016/j.neo.2017.10.005.CrossRefPubMedPubMedCentral

21.

Lai Y, Zhang Z, Li J, Li W, Huang Z, Zhang C, et al. STYK1/NOK correlates with ferroptosis in non-small cell lung carcinoma. Biochem Biophys Res Commun. 2019;519(4):659–66. https://doi.org/10.1016/j.bbrc.2019.09.032.CrossRefPubMed

22.

Nie J, Lin B, Zhou M, Wu L, Zheng T. Role of ferroptosis in hepatocellular carcinoma. J Cancer Res Clin Oncol. 2018;144(12):2329–37. https://doi.org/10.1007/s00432-018-2740-3.CrossRefPubMed

23.

Wang K, Zhang Z, Wang M, Cao X, Qi J, Wang D, et al. Role of GRP78 inhibiting artesunate-induced ferroptosis in KRAS mutant pancreatic cancer cells. Drug Des Dev Ther. 2019;13:2135–44. https://doi.org/10.2147/DDDT.S199459.CrossRef

24.

Wang C, Shi M, Ji J, Cai Q, Zhao Q, Jiang J, et al. Stearoyl-CoA desaturase 1 (SCD1) facilitates the growth and anti-ferroptosis of gastric cancer cells and predicts poor prognosis of gastric cancer. Aging. 2020;12(15):15374–91. https://doi.org/10.18632/aging.103598.CrossRefPubMedPubMedCentral

25.

Friedmann Angeli JP, Krysko DV, Conrad M. Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion. Nat Rev Cancer. 2019;19(7):405–14.CrossRefPubMed

26.

Carbone M, Melino G. Stearoyl CoA desaturase regulates Ferroptosis in ovarian Cancer offering new therapeutic perspectives. Cancer Res. 2019;79(20):5149–50. https://doi.org/10.1158/0008-5472.CAN-19-2453.CrossRefPubMed

27.

Zhang X, Du L, Qiao Y, Zhang X, Zheng W, Wu Q, et al. Ferroptosis is governed by differential regulation of transcription in liver cancer. Redox Biol. 2019;24:101211. https://doi.org/10.1016/j.redox.2019.101211.CrossRefPubMedPubMedCentral

28.

Comincini S, Manai F, Meazza C, Pagani S, Martinelli C, Pasqua N, et al. Identification of Autophagy-Related Genes and Their Regulatory miRNAs Associated with Celiac Disease in Children. Int J Mol Sci. 2017;18(2):18(2). https://doi.org/10.3390/ijms18020391.CrossRef

29.

Zhou Z, Huang R, Chai R, Zhou X, Hu Z, Wang W, et al. Identification of an energy metabolism-related signature associated with clinical prognosis in diffuse glioma. Aging. 2018;10(11):3185–209. https://doi.org/10.18632/aging.101625.CrossRefPubMedPubMedCentral

30.

Liao Y, Wang Y, Cheng M, Huang C, Fan X. Weighted gene Coexpression network analysis of features that control Cancer stem cells reveals prognostic biomarkers in lung adenocarcinoma. Front Genet. 2020;11:311. https://doi.org/10.3389/fgene.2020.00311.CrossRefPubMedPubMedCentral

31.

Liao Y, Xiao H, Cheng M, Fan X. Bioinformatics analysis reveals biomarkers with Cancer stem cell characteristics in lung squamous cell carcinoma. Front Genet. 2020;11:427. https://doi.org/10.3389/fgene.2020.00427.CrossRefPubMedPubMedCentral

32.

Yerukala Sathipati S, Ho SY. Identifying the miRNA signature associated with survival time in patients with lung adenocarcinoma using miRNA expression profiles. Sci Rep. 2017;7(1):7507. https://doi.org/10.1038/s41598-017-07739-y.CrossRefPubMedPubMedCentral

33.

Nziza N, Jeziorski E, Delpont M, Cren M, Chevassus H, Carbasse A, et al. Synovial-Fluid miRNA Signature for Diagnosis of Juvenile Idiopathic Arthritis. Cells. 2019;8(12):8(12). https://doi.org/10.3390/cells8121521.CrossRef

34.

Song P, Jiang B, Liu Z, Ding J, Liu S, Guan W. A three-lncRNA expression signature associated with the prognosis of gastric cancer patients. Cancer Med. 2017;6(6):1154–64. https://doi.org/10.1002/cam4.1047.CrossRefPubMedPubMedCentral

35.

Mao Y, Fu Z, Zhang Y, Dong L, Zhang Y, Zhang Q, et al. A seven-lncRNA signature predicts overall survival in esophageal squamous cell carcinoma. Sci Rep. 2018;8(1):8823. https://doi.org/10.1038/s41598-018-27307-2.CrossRefPubMedPubMedCentral

36.

Zhang X, Ren L, Yan X, Shan Y, Liu L, Zhou J, et al. Identification of immune-related lncRNAs in periodontitis reveals regulation network of gene-lncRNA-pathway-immunocyte. Int Immunopharmacol. 2020;84:106600. https://doi.org/10.1016/j.intimp.2020.106600.CrossRefPubMed

37.

Zhang G, Fan E, Zhong Q, Feng G, Shuai Y, Wu M, et al. Identification and potential mechanisms of a 4-lncRNA signature that predicts prognosis in patients with laryngeal cancer. Hum Genomics. 2019;13(1):36. https://doi.org/10.1186/s40246-019-0230-6.CrossRefPubMedPubMedCentral

38.

Li J, Wang W, Xia P, Wan L, Zhang L, Yu L, et al. Identification of a five-lncRNA signature for predicting the risk of tumor recurrence in patients with breast cancer. Int J Cancer. 2018;143(9):2150–60. https://doi.org/10.1002/ijc.31573.CrossRefPubMedPubMedCentral

39.

Zhu X, Tian X, Yu C, Shen C, Yan T, Hong J, et al. A long non-coding RNA signature to improve prognosis prediction of gastric cancer. Mol Cancer. 2016;15(1):60. https://doi.org/10.1186/s12943-016-0544-0.CrossRefPubMedPubMedCentral

40.

Lu J, Xu F, Lu H. LncRNA PVT1 regulates ferroptosis through miR-214-mediated TFR1 and p53. Life Sci. 2020;260:118305. https://doi.org/10.1016/j.lfs.2020.118305.CrossRefPubMed

41.

Qi W, Li Z, Xia L, Dai J, Zhang Q, Wu C, et al. LncRNA GABPB1-AS1 and GABPB1 regulate oxidative stress during erastin-induced ferroptosis in HepG2 hepatocellular carcinoma cells. Sci Rep. 2019;9(1):16185. https://doi.org/10.1038/s41598-019-52837-8.CrossRefPubMedPubMedCentral

42.

Wang M, Mao C, Ouyang L, Liu Y, Lai W, Liu N, et al. Correction to: Long noncoding RNA LINC00336 inhibits ferroptosis in lung cancer by functioning as a competing endogenous RNA. Cell Death Differ. 2020;27(4):1447. https://doi.org/10.1038/s41418-019-0394-6.CrossRefPubMed

43.

Yang Y, Tai W, Lu N, Li T, Liu Y, Wu W, et al. lncRNA ZFAS1 promotes lung fibroblast-to-myofibroblast transition and ferroptosis via functioning as a ceRNA through miR-150-5p/SLC38A1 axis. Aging. 2020;12(10):9085–102. https://doi.org/10.18632/aging.103176.CrossRefPubMedPubMedCentral

44.

Wang Z, Chen X, Liu N, Shi Y, Liu Y, Ouyang L, et al. A nuclear Long non-coding RNA LINC00618 accelerates Ferroptosis in a manner dependent upon apoptosis. Mol Ther. 2020;29(1):263–74. https://doi.org/10.1016/j.ymthe.2020.09.024.CrossRefPubMedPubMedCentral

45.

Jeong SH, Kim RB, Park SY, Park J, Jung EJ, Ju YT, et al. Nomogram for predicting gastric cancer recurrence using biomarker gene expression. Eur J Surg Oncol. 2020;46(1):195–201. https://doi.org/10.1016/j.ejso.2019.09.143.CrossRefPubMed

46.

Wang S, Chai K, Chen J. A novel prognostic nomogram based on 5 long non-coding RNAs in clear cell renal cell carcinoma. Oncol Lett. 2019;18(6):6605–13. https://doi.org/10.3892/ol.2019.11009.CrossRefPubMedPubMedCentral

47.

Szikszai K, Krejcik Z, Klema J, Loudova N, Hrustincova A, Belickova M, et al. LncRNA Profiling Reveals That the Deregulation of H19, WT1-AS, TCL6, and LEF1-AS1 Is Associated with Higher-Risk Myelodysplastic Syndrome. Cancers. 2020;12(10):12(10). https://doi.org/10.3390/cancers12102726.CrossRef

Title: A novel ferroptosis-related lncRNA signature for prognosis prediction in gastric cancer
Authors: Jianming Wei
Ye Zeng
Xibo Gao
Tong Liu
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Gastric Cancer
Gastric Cancer
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08975-2

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Image Credits

ASCO 2024 | Highlights of the Day: Breast cancer – metastatic/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Gynecologic Cancer/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Breast Cancer – local/regional/adjuvant/© 2024 American Society of Clinical Oncology, all rights reserved., Melanoma/© selvanegra / Getty Images / iStock, Antibody drug conjugated with cytotoxic payload/© Love Employee / Getty images / iStock

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

A case-control study of a combination of single nucleotide polymorphisms and clinical parameters to predict clinically relevant toxicity associated with fluoropyrimidine and platinum-based chemotherapy in gastric cancer

Identification of prognostic markers for hepatocellular carcinoma based on the epithelial-mesenchymal transition-related gene BIRC5

Mechanism and risk factors of nausea and vomiting after TACE: a retrospective analysis

A novel PDX modeling strategy and its application in metabolomics study for malignant pleural mesothelioma

EML4-ALK induces cellular senescence in mortal normal human cells and promotes anchorage-independent growth in hTERT-transduced normal human cells

Soft tissue masses: distribution of entities and rate of malignancy in small lesions